SEQUENCE LISTING

<110> Immunogen, Inc.
CARRIGAN, Christina N.
WHITEMAN, Kathleen R.
PAYNE, Gillian
LADD, Sharron

<120> METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY

<130> 2921.015PC01

<140> PCT/US2012/031544
<141> 2012-03-30

<150> US 61/471,007
<151> 2011-04-01

<160> 11

<170> PatentIn version 3.5

<210> 1
<211> 257
<212> PRT
<213> Homo sapiens

<400> 1

Met Ala Gln Arg Met Thr Thr Gln Leu Leu Leu Leu Leu Val Trp Val
1 5 10 15

Ala Val Val Gly Glu Ala Gln Thr Arg Ile Ala Trp Ala Arg Thr Glu
20 25 30

Leu Leu Asn Val Cys Met Asn Ala Lys His His Lys Glu Lys Pro Gly
35 40 45

Pro Glu Asp Lys Leu His Glu Gln Cys Arg Pro Trp Arg Lys Asn Ala
50 55 60

Cys Cys Ser Thr Asn Thr Ser Gln Glu Ala His Lys Asp Val Ser Tyr
65 70 75 80

Leu Tyr Arg Phe Asn Trp Asn His Cys Gly Glu Met Ala Pro Ala Cys
85 90 95

Lys Arg His Phe Ile Gln Asp Thr Cys Leu Tyr Glu Cys Ser Pro Asn
100 105 110

Leu Gly Pro Trp Ile Gln Gln Val Asp Gln Ser Trp Arg Lys Glu Arg
115 120 125

Val Leu Asn Val Pro Leu Cys Lys Glu Asp Cys Glu Gln Trp Trp Glu
130 135 140

Asp Cys Arg Thr Ser Tyr Thr Cys Lys Ser Asn Trp His Lys Gly Trp
145 150 155 160

```
Asn Trp Thr Ser Gly Phe Asn Lys Cys Ala Val Gly Ala Ala Cys Gln
                165                 170                 175

Pro Phe His Phe Tyr Phe Pro Thr Pro Thr Val Leu Cys Asn Glu Ile
            180                 185                 190

Trp Thr His Ser Tyr Lys Val Ser Asn Tyr Ser Arg Gly Ser Gly Arg
        195                 200                 205

Cys Ile Gln Met Trp Phe Asp Pro Ala Gln Gly Asn Pro Asn Glu Glu
    210                 215                 220

Val Ala Arg Phe Tyr Ala Ala Ala Met Ser Gly Ala Gly Pro Trp Ala
225                 230                 235                 240

Ala Trp Pro Phe Leu Leu Ser Leu Ala Leu Met Leu Leu Trp Leu Leu
                245                 250                 255

Ser
```

<210> 2
<211> 771
<212> DNA
<213> Homo sapiens

<400> 2

```
atggctcagc ggatgacaac acagctgctg ctccttctag tgtgggtggc tgtagtaggg       60

gaggctcaga caaggattgc atgggccagg actgagcttc tcaatgtctg catgaacgcc      120

aagcaccaca aggaaaagcc aggccccgag gacaagttgc atgagcagtg tcgaccctgg      180

aggaagaatg cctgctgttc taccaacacc agccaggaag cccataagga tgtttcctac      240

ctatatagat tcaactggaa ccactgtgga gagatggcac ctgcctgcaa acggcatttc      300

atccaggaca cctgcctcta cgagtgctcc cccaacttgg ggccctggat ccagcaggtg      360

gatcagagct ggcgcaaaga gcgggtactg aacgtgcccc tgtgcaaaga ggactgtgag      420

caatggtggg aagattgtcg cacctcctac acctgcaaga gcaactggca caagggctgg      480

aactggactt cagggtttaa caagtgcgca gtgggagctg cctgccaacc tttccatttc      540

tacttcccca cacccactgt tctgtgcaat gaaatctgga ctcactccta caaggtcagc      600

aactacagcc gagggagtgg ccgctgcatc cagatgtggt tcgacccagc ccagggcaac      660

cccaatgagg aggtggcgag gttctatgct gcagccatga gtggggctgg gccctgggca      720

gcctggcctt tcctgcttag cctggcccta atgctgctgt ggctgctcag c               771
```

<210> 3
<211> 118
<212> PRT
<213> Artificial Sequence

<220>

<223> huMov19 vHC

<400> 3

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
            20                  25                  30

Phe Met Asn Trp Val Lys Gln Ser Pro Gly Gln Ser Leu Glu Trp Ile
        35                  40                  45

Gly Arg Ile His Pro Tyr Asp Gly Asp Thr Phe Tyr Asn Gln Lys Phe
    50                  55                  60

Gln Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala His
65                  70                  75                  80

Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Phe Ala Val Tyr Tyr Cys
                85                  90                  95

Thr Arg Tyr Asp Gly Ser Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110

Thr Val Thr Val Ser Ser
        115
```

<210> 4
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> huMov19 vLCv1.00

<400> 4

```
Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15

Gln Pro Ala Ile Ile Ser Cys Lys Ala Ser Gln Ser Val Ser Phe Ala
            20                  25                  30

Gly Thr Ser Leu Met His Trp Tyr His Gln Lys Pro Gly Gln Gln Pro
        35                  40                  45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ala Gly Val Pro Asp
    50                  55                  60

Arg Phe Ser Gly Ser Gly Ser Lys Thr Asp Phe Thr Leu Asn Ile Ser
65                  70                  75                  80

Pro Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Arg
                85                  90                  95
```

Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105 110

<210> 5
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> huMov19 vLCv1.60

<400> 5

Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Pro Ala Ile Ile Ser Cys Lys Ala Ser Gln Ser Val Ser Phe Ala
20 25 30

Gly Thr Ser Leu Met His Trp Tyr His Gln Lys Pro Gly Gln Gln Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ala Gly Val Pro Asp
50 55 60

Arg Phe Ser Gly Ser Gly Ser Lys Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Pro Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Arg
85 90 95

Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105 110

<210> 6
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> huMov19 vHC CDR1

<400> 6

Gly Tyr Phe Met Asn
1 5

<210> 7
<211> 17
<212> PRT
<213> Artificial sequence

<220>
<223> Kabat Defined Mov19 HC CDR2 Human

<400> 7

Arg Ile His Pro Tyr Asp Gly Asp Thr Phe Tyr Asn Gln Lys Phe Gln

1 5 10 15

Gly

<210> 8
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> huMov19 vHC CDR3

<400> 8

Tyr Asp Gly Ser Arg Ala Met Asp Tyr
1 5

<210> 9
<211> 15
<212> PRT
<213> Artificial sequence

<220>
<223> huMov19 vLC CDR1

<400> 9

Lys Ala Ser Gln Ser Val Ser Phe Ala Gly Thr Ser Leu Met His
1 5 10 15

<210> 10
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> huMov19 vLC CDR2

<400> 10

Arg Ala Ser Asn Leu Glu Ala
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> huMov19 vLC CDR3

<400> 11

Gln Gln Ser Arg Glu Tyr Pro Tyr Thr
1 5